ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that members of the management team will present at the following upcoming conferences:
- Australia-China Biotech Invest 2017 on Monday, March 27 at 10:35am (CST) at the Shanghai Marriott Hotel City Centre in Shanghai, China;
- The Digital Health Show, Health Innovation Theatre on Wednesday, March 29 at 10:30am (AEDT) at the Melbourne Convention and Exhibition Centre in Melbourne, Australia; and
- Myriad on Thursday, March 30 at 3:30pm (AEST) at the Brisbane Powerhouse in Brisbane, Australia.
The company is also this week participating in a bespoke tour of Silicon Valley after being awarded ‘Best Tech IPO/Venture Capital Raising’ at the 2016 Talent Unleashed Global Awards in August last year.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.